...previously GlycoVaxyn AG, was valued at $212 million when GSK acquired it in 2015 (see “GlycoVaxyn...
...LimmaTech’s platforms don’t overlap as they use different conjugating enzymes and transfer different polysaccharides. Whereas GlycoVaxyn’s...

...meningococcal disease caused by Neisseria meningitidis serogroup B Accelerated approval (U.S.); Ph III (EU) PF-06290510 Staphylococcus aureus vaccine...

...NYSE:PFE), New York, N.Y. Product: SA4Ag ( PF-06290510 ) Business: Infectious Molecular target: NA Description: Staphylococcus aureus vaccine...

...GlaxoSmithKline acquired the remaining shares of GlycoVaxyn it did not already own for $190 million, which...
...a minority stake in GlycoVaxyn in a 2012 deal that gave the pharma access to GlycoVaxyn’s...
...vaccines. The asset swap is expected to close this half (see BioCentury, April 28, 2014). GlycoVaxyn...

...plc (LSE:GSK;NYSE:GSK) paid $190 million (L124.7 million) to acquire the remaining shares of vaccine developer GlycoVaxyn...
...a minority stake in GlycoVaxyn in a 2012 deal that gave the pharma access to GlycoVaxyn's...
...asset swap is expected to close this half (see BioCentury Extra, April 4, 2014) . GlycoVaxyn's...

...in the vaccine at 30 days post-vaccination. The data triggered an undisclosed milestone payment to GlycoVaxyn...
...Janssen will be responsible for further development and worldwide commercialization. The vaccine was developed using GlycoVaxyn’s...
...of protein-polysaccharide complexes in E. coli via recombinant DNA technology (see BioCentury, Jan. 7, 2013). GlycoVaxyn...

...evaluate the Glycoconjugate ExPEC vaccine in 180 women affected by recurrent urinary tract infection (UTI). GlycoVaxyn...
...Janssen will be responsible for further development and worldwide commercialization. The vaccine was developed using GlycoVaxyn’s...
...of protein-polysaccharide complexes in E. coli via recombinant DNA technology (see BioCentury, Jan. 7, 2013). GlycoVaxyn...

...meningitis vaccine in Phase III testing that is expected to be launched in 2017-18, a Staphylococcus aureus vaccine...

...will use GlycoVaxyn's bio-conjugation technology to develop a multivalent bacterial vaccine. Under the three-year deal, GlycoVaxyn...
...proof of concept, after which Janssen will be responsible for further development and worldwide commercialization. GlycoVaxyn...
...for details. In December, GlycoVaxyn partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) to use GlycoVaxyn's...